Patents by Inventor David FitzGerald

David FitzGerald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6099842
    Abstract: Single chain immunotoxins directed at the human transferrin receptor using PCR based methods are described. Anti-TFR(Fv)-PE40 contains DNA for the antigen binding portion (Fv) of a monoclonal antibody directed at the human transferrin receptor fused to the DNA for a 40,000 molecular weight fragment of Pseudomonas exotoxin (PE40). In another fusion protein, DT388-anti-TFR(Fv), DNA for the antigen binding portions of the anti-TFR antibody has been fused to the DNA encoding a truncated form of Diphtheria toxin. In anti-TFR(Fv)-PE40, the single chain antibody precedes the toxin whereas in DT388-anti-TFR(Fv) the single chain antibody is at the carboxyl end of toxin. The proteins encoded by these gene fusions were expressed in E.coli and purified by conventional chromatographic techniques to near homogeneity.
    Type: Grant
    Filed: December 3, 1990
    Date of Patent: August 8, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira Pastan, Vijay Chaudhary, David FitzGerald, Janendra Batra
  • Patent number: 6051405
    Abstract: The present invention describes constructs encoding recombinant scFv-toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.
    Type: Grant
    Filed: April 8, 1992
    Date of Patent: April 18, 2000
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Protein Design Labs, Inc.
    Inventors: David FitzGerald, Vijay Kumar Chaudhary, Ira Harry Pastan, Thomas Alexander Waldmann, Cary L Queen
  • Patent number: 5990296
    Abstract: This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.
    Type: Grant
    Filed: December 3, 1996
    Date of Patent: November 23, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira Pastan, Mark Willingham, David Fitzgerald, Ulrich Brinkmann, Lee Pai
  • Patent number: 5782787
    Abstract: An absorbent wound dressing (1) includes a polymer foam layer (3) having a plurality of discrete zones (2) on at least one surface (4) of the foam layer, the material forming the zones being less swellable than the foam layer material, such that when the dressing is placed with the zones of polymeric material in contact with a wet surface, the zones move apart as the foam layer absorbs fluid and swells.
    Type: Grant
    Filed: August 14, 1995
    Date of Patent: July 21, 1998
    Assignee: Smith & Nephew plc
    Inventor: David Fitzgerald Webster
  • Patent number: 5705156
    Abstract: Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive charge provides markedly changed exotoxins. Conjugation of the new exotoxins with suitable targeting agents provides cytocidal specificity for killing desired cellular entities.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 6, 1998
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, David Fitzgerald, Vijay K. Chaudhary
  • Patent number: 5705163
    Abstract: A target-specific, cytotoxic, recombinant Pseudomonas exotoxin is described. Such toxins are made by inserting specific recognition molecules at specific cloning sites in at least domain III near the carboxyl terminus of the PE molecule. Various modifications of the carboxyl terminus of the PE molecule to increase cytotoxicity are set forth. Multifunctional, recombinant, cytotoxic fusion proteins containing at least two different recognition molecules are provided for killing cells expressing receptors to which the recognition molecules bind with specificity. Methods for producing novel recombinant PE molecules with specific properties are described.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 6, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services, National Institutes of Health
    Inventors: Ira Pastan, Vijay K. Chaudhary, David Fitzgerald
  • Patent number: 5696237
    Abstract: The present invention describes recombinant antibody toxin fusion proteins which selectively kill cells bearing appropriate antigens or receptors.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 9, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: David FitzGerald, Vijay Kumar Chaudhary, Ira Harry Pastan, Thomas Alexander Waldmann, Cary L. Queen
  • Patent number: 5608039
    Abstract: This invention provides for recombinant single chain antibodies capable of specifically binding to a Lewis.sup.Y -related carbohydrate antigen and fusion proteins comprising these antibodies. More particularly, the invention provides for single chain Fv regions of the monoclonal antibody B3. The invention also provides for a method of improving the binding affinity of antibodies lacking a serine at position 95 of the V.sub.H region that involves mutating position 95 to a serine.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: March 4, 1997
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, Mark Willingham, David Fitzgerald, Ulrich Brinkmann, Lee Pai
  • Patent number: 5587455
    Abstract: A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.
    Type: Grant
    Filed: November 8, 1994
    Date of Patent: December 24, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Edward A. Berger, Bernard Moss, Thomas R. Fuerst, Ira Pastan, David Fitzgerald, Tamio Mizukami, Vijay K. Chaudhary
  • Patent number: 5512658
    Abstract: Improved Pseudomonas exotoxins of low animal toxicity and high cytocidal activity are described. Substitution of positively charged amino acid residues with an amino acid residue without a positive charge provides markedly changed exotoxins. Conjugation of the new exotoxins with suitable targeting agents provides cytocidal specificity for killing desired cellular entities.
    Type: Grant
    Filed: October 1, 1993
    Date of Patent: April 30, 1996
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, David Fitzgerald, Vijay K. Chaudhary
  • Patent number: 5458878
    Abstract: A target-specific, cytotoxic, recombinant Pseudomonas exotoxin is described. Such toxins are made by inserting specific recognition molecules at specific cloning sites in at least domain III near the carboxyl terminus of the PE molecule. Various modifications of the carboxyl terminus of the PE molecule to increase cytotoxicity are set forth. Multifunctional, recombinant, cytotoxic fusion proteins containing at least two different recognition molecules are provided for killing cells expressing receptors to which the recognition molecules bind with specificity. Methods for producing novel recombinant PE molecules with specific properties are described.
    Type: Grant
    Filed: May 14, 1990
    Date of Patent: October 17, 1995
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ira Pastan, Vijay K. Chaudhary, David Fitzgerald
  • Patent number: 5428143
    Abstract: A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: June 27, 1995
    Assignee: United States of America
    Inventors: Edward A. Berger, Bernard Moss, Thomas R. Fuerst, Ira Pastan, David Fitzgerald, Tamio Mizukami, Vijay K. Chaudhary
  • Patent number: 5206353
    Abstract: A chimeric gene directing the synthesis of hybrid recombinant fusion protein in a suitable expression vector has been constructed. The fusion protein possesses the property of selective cytotoxicity against specific virus-infected cells. A CD4(178)-PE40 hybrid fusion protein has been made for selectively killing HIV-infected cells.
    Type: Grant
    Filed: July 22, 1988
    Date of Patent: April 27, 1993
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Edward A. Berger, Bernard Moss, Thomas R. Fuerst, Ira Pastan, David Fitzgerald, Tamio Mizukami, Vijay K. Chaudhary
  • Patent number: 5082927
    Abstract: The present invention provides a chimeric protein IL4-PE40 which selectively kills IL4 receptor bearing cells. A mutant form of the protein is also provided.
    Type: Grant
    Filed: May 12, 1989
    Date of Patent: January 21, 1992
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira Pastan, David FitzGerald, Masato Ogata
  • Patent number: 4892827
    Abstract: Modified Pseudomonas exotaxins which comprise deletions in at least domain 1A are taught. The toxins exhibit reduced cytotoxicity.
    Type: Grant
    Filed: September 24, 1986
    Date of Patent: January 9, 1990
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira H. Pastan, Sankar Adhya, David Fitzgerald
  • Patent number: 4355969
    Abstract: Improving the combustion of a fuel by providing negatively charged ions in water to molecularly excite the water, creating an emulsion composed of tiny droplets of the ion charged water coated with fuel oil, and introducing the emulsion of excited fuel coated water droplets with oxidizing gas into a combustion zone.
    Type: Grant
    Filed: May 29, 1980
    Date of Patent: October 26, 1982
    Assignee: FND Company
    Inventors: Kenneth L. Nelson, David FitzGerald
  • Patent number: D455609
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: April 16, 2002
    Assignee: GMPC
    Inventors: Gary Mandel, David FitzGerald